Apellis Pharmaceuticals, Inc. APLS
At closeMay 15, 2026, 4:00 PM EDT
After hours · May 15, 4:00 PM ET
52-week range unavailable
- YTD
- +63.34%
- 1 year
- +150.79%
- Market cap
- 5.25B
- Profit margin
- 12.06%
- YTD return
- +63.34%
- 1-year return
- +150.79%
- Volume
- 28.64M
- Open
- 41.05
- Previous close
- 41.03
- Day's range
- 41.03 – 41.05
- Earnings date
- Jul 30, 2026
Key statistics
- Enterprise value
- 5.32B
- PEG ratio
- 0.07
- Price / sales
- 0.00
- Price / book
- 12.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 4
- Return on equity
- 39.71%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy10
- Buy4
- Hold8
- Sell0
- Strong sell0
Next earnings
Jul 30, 2026
Expected Jul 30, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 30, 2026 | Jun 30, 2026 | -0.33 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | -0.38 | 0.15 | +0.53 | +139.47% |
| Feb 24, 2026 | Dec 31, 2025 | -0.39 | -0.47 | -0.08 | -20.51% |
| Oct 30, 2025 | Sep 30, 2025 | 1.03 | 1.67 | +0.64 | +62.14% |
| Jul 31, 2025 | Jun 30, 2025 | -0.44 | -0.33 | +0.11 | +25.00% |
| May 7, 2025 | Mar 31, 2025 | -0.36 | -0.74 | -0.38 | -105.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | init | — | Sector Perform |
| Oct 16, 2024 | William Blair | init | — | Outperform |
| Sep 24, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Sep 23, 2024 | Baird | main | Outperform | Outperform |
| Sep 20, 2024 | Mizuho | main | Neutral | Neutral |
| Sep 20, 2024 | Needham | reit | Buy | Buy |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 705
- Website
- apellis.com
News
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout 
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer 
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer 
Why Is Biogen Stock Falling Thursday? 
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy 
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 
Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals 
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics 
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates 
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
Your note
Sign in to keep a note on APLS — it syncs with the Stock Master app.